Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cellectis S A currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions are distributed across 4 distinct examiners, indicating a range of individual examination styles. Furthermore, the prosecution activity spans 4 distinct art units, which suggests a broad technical scope within the company's specialized field.
The busiest examiner for the company is WEN, SHARON X, who is responsible for 1 pending office action. This means that the workload is distributed such that each of the 4 distinct examiners handles exactly one matter. This lack of concentration across the technical divisions implies that the company's patent strategy must account for the varied standards and technical focuses of four different examination groups simultaneously.
With 4 distinct examiners, the company does not have a single primary examiner relationship. Instead, the 4 distinct art units involved represent a wide array of technical challenges within Biotechnology & Pharmaceuticals. The fact that WEN, SHARON X only manages 1 pending office action highlights the decentralized nature of the company's current prosecution efforts across its 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEN, SHARON X | 1 | 56.9% | +32.6% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002229 | Method for determining potency of chimeric antigen receptor expressing immune cells | HOWARD, ZACHARY C | 27d |
| 18556957 | NEW ANTI-MUC1 CARS AND GENE EDITED IMMUNE CELLS FOR SOLID TUMORS CANCER IMMUNOTHERAPY | WEN, SHARON X | — |
| 17996733 | METHODS FOR TARGETED INSERTION OF EXOGENOUS SEQUENCES IN CELLULAR GENOMES | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005284 | T-CELLS EXPRESSING IMMUNE CELL ENGAGERS IN ALLOGENIC SETTINGS | NICOL, ALEXANDER W | 26d overdue |
| 18002229 | Method for determining potency of chimeric antigen receptor expressing immune cells | HOWARD, ZACHARY C | 27d |
| 18556957 | NEW ANTI-MUC1 CARS AND GENE EDITED IMMUNE CELLS FOR SOLID TUMORS CANCER IMMUNOTHERAPY | WEN, SHARON X | — |
| 17996733 | METHODS FOR TARGETED INSERTION OF EXOGENOUS SEQUENCES IN CELLULAR GENOMES | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1674 | 1 |
| 1634 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556957 | NEW ANTI-MUC1 CARS AND GENE EDITED IMMUNE CELLS FOR SOLID TUMORS CANCER IMMUNOTHERAPY | WEN, SHARON X | 1641 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18002229 | Method for determining potency of chimeric antigen receptor expressing immune cells | HOWARD, ZACHARY C | 1674 | §102§112 | Final Rejection | 27d | Pending | May 23, 2023 |
| 18005284 | T-CELLS EXPRESSING IMMUNE CELL ENGAGERS IN ALLOGENIC SETTINGS | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | 26d overdue | Pending | Jan 12, 2023 |
| 17996733 | METHODS FOR TARGETED INSERTION OF EXOGENOUS SEQUENCES IN CELLULAR GENOMES | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial